WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2013123451) LNA ANTISENSE OLIGONUCLEOTIDES FOR THE MODULATION OF MYC EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2013/123451    International Application No.:    PCT/US2013/026515
Publication Date: 22.08.2013 International Filing Date: 15.02.2013
IPC:
A61K 48/00 (2006.01)
Applicants: ENZON PHARMACEUTICALS, INC. [US/US]; 20 Kingsbridge Road Piscataway, New Jersey 08854 (US).
DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Ave. Boston, Massachusetts 02215 (US)
Inventors: BANDARU, Rajanikanth; (US).
ZHANG, Yixian; (US).
QU, Zhengxing; (US).
GREENBERGER, Lee; (US).
OTT, Christopher; (US).
BRADNER, James Elliot; (US)
Agent: GIDDINGS, Barton W.; STOEL RIVES LLP 201 S. Main Street, Suite 1100 Salt Lake City, Utah 84111 (US)
Priority Data:
61/598,995 15.02.2012 US
Title (EN) LNA ANTISENSE OLIGONUCLEOTIDES FOR THE MODULATION OF MYC EXPRESSION
(FR) OLIGONUCLÉOTIDES ANTI-SENS LNA POUR LA MODULATION DE L'EXPRESSION DE MYC
Abstract: front page image
(EN)The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.
(FR)La présente invention concerne des composés oligonucléotidiques (oligomères) qui ciblent l'ARNm Myc dans une cellule, conduisant à une expression réduite de Myc. La réduction de l'expression de Myc est bénéfique pour le traitement de certains troubles, tels que des troubles hyperprolifératifs (par exemple, le cancer). La présente invention concerne des compositions thérapeutiques comprenant des oligomères et des méthodes pour moduler l'expression de Myc à l'aide desdits oligomères, y compris des méthodes de traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)